Ancrod Stroke Program

Ancrod Stroke Program

Purpose: The primary purpose of these studies is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.

Condition: Stroke, cerebral ischemia, brain infarction

Official Title:

ASP-I- Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke.

ASP-II- A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke.

Treatment: Ancrod (Viprinex™)

Phase: Phase III (650 Subjects are planned per study)

Study Director: Warren W. Wasiewski, M.D. F.A.A.P. Neurobiological Technologies, Inc.
Tel: 201.941.8911

Study ID Number:
NTI-ASP-0502 and NTI-ASP-0503
(ASP-I and ASP-II)

Eligibility: Inclusion Criteria:

  • Either Gender
  • Acute, Ischemic stroke with first symptoms within 6 hours of beginning treatment
  • ≥18 Years old
  • Baseline NIHSS 5-25

Exclusion Criteria:

  • Intracranial, extravascular blood on CT
  • Hypertension (systolic >185; diastolic >105 mm Hg
  • Baseline fibrinogen level < 100 mg/dL
  • Thrombocytopenia (<100,000/mm³)
  • Recent (<3 days) or anticipated(<5 days) use of a thrombolytic agent
  • Recent (<14 days) or anticipated surgery


If you are interested in participating in the ASP-I or ASP-II Clinical Trial, kindly fax the below completed forms to:

Clinical Operations:
 Fax Number: 201-941-8355

For more information on the ASP-I or ASP-II Clinical Trials contact:

Or visit the Stroke Center website:
http://www.strokecenter.org